首页 > 最新文献

Journal of Neurological Surgery Reports最新文献

英文 中文
Proton Therapy for Chondrosarcoma 软骨肉瘤的质子治疗
Q4 CLINICAL NEUROLOGY Pub Date : 2023-10-16 DOI: 10.1055/a-2192-5775
Dennis M. Tang, Raffaello Cutri, Arthur Wu, Chirag Patil, Zachary Zumsteg
Chondrosarcoma is a type of an endochondral bone malignancy which is primarily treated surgically with radiation therapy used in the adjuvant setting or in cases of unresectable disease. Proton therapy has potential advantages compared to traditional photon therapy for treatment of tumors in close proximity to critical structures due to the theoretic lower exit dose. Studies have shown improved survival in patients with skull base chondrosarcoma who undergo proton therapy. However, there is a lack of randomized data. Further studies are needed to define the role of proton therapy in treatment of skull base chondrosarcoma.
软骨肉瘤是一种软骨内骨恶性肿瘤,主要通过手术治疗,在辅助设置或不可切除的疾病的情况下使用放射治疗。相对于传统的光子治疗而言,质子治疗在治疗靠近关键结构的肿瘤方面具有潜在的优势,因为理论上的出口剂量较低。研究表明,接受质子治疗的颅底软骨肉瘤患者生存率提高。然而,缺乏随机数据。需要进一步的研究来确定质子治疗在颅底软骨肉瘤中的作用。
{"title":"Proton Therapy for Chondrosarcoma","authors":"Dennis M. Tang, Raffaello Cutri, Arthur Wu, Chirag Patil, Zachary Zumsteg","doi":"10.1055/a-2192-5775","DOIUrl":"https://doi.org/10.1055/a-2192-5775","url":null,"abstract":"Chondrosarcoma is a type of an endochondral bone malignancy which is primarily treated surgically with radiation therapy used in the adjuvant setting or in cases of unresectable disease. Proton therapy has potential advantages compared to traditional photon therapy for treatment of tumors in close proximity to critical structures due to the theoretic lower exit dose. Studies have shown improved survival in patients with skull base chondrosarcoma who undergo proton therapy. However, there is a lack of randomized data. Further studies are needed to define the role of proton therapy in treatment of skull base chondrosarcoma.","PeriodicalId":44256,"journal":{"name":"Journal of Neurological Surgery Reports","volume":"41 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136142468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CIC-DUX4 Sarcoma Involving the Skull Base: A Rare Presentation and Review of the Literature. CIC-DUX4涉及颅底的肉瘤:罕见的介绍和文献综述。
IF 0.5 Q4 CLINICAL NEUROLOGY Pub Date : 2023-10-13 eCollection Date: 2023-10-01 DOI: 10.1055/a-2166-5688
Sara B Hobday, Leila J Mady, Alec M Jacobson, Christopher H Rassekh

Background  CIC-DUX4 sarcoma is a rare, aggressive tumor that is difficult to diagnose. Although it is closely related to Ewing's sarcoma, each is a distinct pathologic entity and both have been previously reported in the skin, lymph nodes, and viscera. We report the first description of CIC-DUX4 involving the posterior cranial fossa and review the distinctive symptomatology, morphology, immunoprofile, and genetic signature that differentiate this rare tumor. Case Report  A 32-year-old man presented with an enlarging right lateral neck mass, progressive hoarseness, and orofacial pain. Biopsy revealed a high-grade undifferentiated malignant neoplasm. Imaging demonstrated an 8-cm mass in the right neck extending to the skull base and abutting the carotid sheath, in addition to pulmonary nodules and pelvic lymphadenopathy. Despite initial response to chemotherapy, he experienced disease progression and underwent surgical resection, radical neck dissection, and brachytherapy. Definitive pathologic diagnosis was achieved with next-generation sequencing. Within weeks of treatment, he developed symptoms reflecting progression of disease involving the neck, posterior cranial fossa, and lung. Adjuvant chemotherapy was planned, but the patient succumbed to his disease prior to initiation of further therapy. Conclusion  CIC-DUX4 sarcomas are uncommon and can progress rapidly. Diagnosis requires either fluorescence in situ hybridization or next-generation sequencing. Due to its rarity, there is no standard-of-care treatment for this tumor and further investigations are needed to understand disease behavior and develop targeted therapeutic modalities.

背景 CIC-DUX4肉瘤是一种罕见的侵袭性肿瘤,很难诊断。尽管它与尤因肉瘤密切相关,但每种肉瘤都是一种不同的病理实体,两者都曾在皮肤、淋巴结和内脏中报道过。我们报道了涉及后颅窝的CIC-DUX4的首次描述,并回顾了区分这种罕见肿瘤的独特症状、形态学、免疫组织化学和遗传特征。案例报告 一名32岁的男子表现为右侧颈部肿块增大,声音嘶哑,口面疼痛。活组织检查显示为高度未分化恶性肿瘤。影像学显示,右颈部有一个8厘米的肿块,延伸至颅底,紧贴颈动脉鞘,此外还有肺结节和盆腔淋巴结病。尽管最初对化疗有反应,但他经历了疾病进展,并接受了手术切除、根治性颈清扫和近距离放射治疗。通过下一代测序获得了明确的病理诊断。在治疗的几周内,他出现了反映颈部、后颅窝和肺部疾病进展的症状。计划进行辅助化疗,但患者在开始进一步治疗之前就死于疾病。结论 CIC-DUX4肉瘤不常见,进展迅速。诊断需要荧光原位杂交或下一代测序。由于其罕见性,该肿瘤没有标准的护理治疗,需要进一步研究以了解疾病行为并开发有针对性的治疗模式。
{"title":"CIC-DUX4 Sarcoma Involving the Skull Base: A Rare Presentation and Review of the Literature.","authors":"Sara B Hobday,&nbsp;Leila J Mady,&nbsp;Alec M Jacobson,&nbsp;Christopher H Rassekh","doi":"10.1055/a-2166-5688","DOIUrl":"10.1055/a-2166-5688","url":null,"abstract":"<p><p><b>Background</b>  CIC-DUX4 sarcoma is a rare, aggressive tumor that is difficult to diagnose. Although it is closely related to Ewing's sarcoma, each is a distinct pathologic entity and both have been previously reported in the skin, lymph nodes, and viscera. We report the first description of CIC-DUX4 involving the posterior cranial fossa and review the distinctive symptomatology, morphology, immunoprofile, and genetic signature that differentiate this rare tumor. <b>Case Report</b>  A 32-year-old man presented with an enlarging right lateral neck mass, progressive hoarseness, and orofacial pain. Biopsy revealed a high-grade undifferentiated malignant neoplasm. Imaging demonstrated an 8-cm mass in the right neck extending to the skull base and abutting the carotid sheath, in addition to pulmonary nodules and pelvic lymphadenopathy. Despite initial response to chemotherapy, he experienced disease progression and underwent surgical resection, radical neck dissection, and brachytherapy. Definitive pathologic diagnosis was achieved with next-generation sequencing. Within weeks of treatment, he developed symptoms reflecting progression of disease involving the neck, posterior cranial fossa, and lung. Adjuvant chemotherapy was planned, but the patient succumbed to his disease prior to initiation of further therapy. <b>Conclusion</b>  CIC-DUX4 sarcomas are uncommon and can progress rapidly. Diagnosis requires either fluorescence in situ hybridization or next-generation sequencing. Due to its rarity, there is no standard-of-care treatment for this tumor and further investigations are needed to understand disease behavior and develop targeted therapeutic modalities.</p>","PeriodicalId":44256,"journal":{"name":"Journal of Neurological Surgery Reports","volume":"84 4","pages":"e124-e128"},"PeriodicalIF":0.5,"publicationDate":"2023-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/62/73/10-1055-a-2166-5688.PMC10575739.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41239697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anterior Skull Base Osteoradionecrosis in the Age of Intensity-Modulated Radiation Therapy: A Case Series. 强度调节放射治疗时代的前颅底放射性骨坏死:一个病例系列。
IF 0.5 Q4 CLINICAL NEUROLOGY Pub Date : 2023-09-27 eCollection Date: 2023-07-01 DOI: 10.1055/a-2164-8637
Nikitha Kosaraju, Huan Zhang, Sharon Qi, Robert Chin, Marilene B Wang

Background  Despites advances in radiation technology, skull base osteoradionecrosis (ORN) continues to be a rare, devastating, and hard to treat complication of radiotherapy. We present three cases of anterior skull base ORN in a cohort treated with intensity-modulated radiation therapy (IMRT). Case Series  Three patients developed anterior skull base ORN after receiving at least one round of IMRT. ORN was diagnosed through either nasal endoscopy or imaging findings. The first was a 59-year-old woman with a sinonasal squamous cell carcinoma. Her chemoradiation history was notable for reirradiation and a high dose of radiation (143.3 Gy). The second was a 55-year-old man with recurrent nasopharyngeal carcinoma, whose history was notable for a high dose of radiation (∼140 Gy) and for being reirradiated. The final patient was a 37-year-old woman with an unremarkable history who received radiotherapy (65.0 Gy) for an esthesioneuroblastoma. One patient was asymptomatic and did not receive ORN-specific therapy. The other two were treated with a combination of medical and surgical intervention with successful short-term outcomes (no evidence of infection). Conclusion  Anterior skull base ORN can be treated through conservative and surgical means to achieve successful short-term outcomes. Further investigation of long-term outcomes is warranted.

背景 尽管放射治疗技术取得了进步,但颅底放射性骨坏死(ORN)仍然是一种罕见的、毁灭性的、难以治疗的放射治疗并发症。我们在一个接受强度调节放射治疗(IMRT)的队列中报告了三例前颅底ORN。案例系列 三名患者在接受至少一轮IMRT后出现前颅底ORN。ORN是通过鼻内镜或影像学检查诊断的。第一位是一位59岁的女性,患有鼻窦鳞状细胞癌。她的放化疗史以再次放疗和高剂量放疗而闻名(143.3 Gy)。第二位是一位55岁的鼻咽癌复发患者,他的病史以高剂量辐射(~140 Gy)和再次照射而闻名。最后一名患者是一名37岁的女性,病史不明显,接受了放射治疗(65.0 Gy)治疗感觉神经母细胞瘤。一名患者无症状,未接受ORN特异性治疗。另外两名患者接受了内科和外科联合干预治疗,取得了成功的短期效果(没有感染的证据)。结论 前颅底ORN可以通过保守和外科手段进行治疗,以获得成功的短期结果。有必要对长期结果进行进一步调查。
{"title":"Anterior Skull Base Osteoradionecrosis in the Age of Intensity-Modulated Radiation Therapy: A Case Series.","authors":"Nikitha Kosaraju,&nbsp;Huan Zhang,&nbsp;Sharon Qi,&nbsp;Robert Chin,&nbsp;Marilene B Wang","doi":"10.1055/a-2164-8637","DOIUrl":"https://doi.org/10.1055/a-2164-8637","url":null,"abstract":"<p><p><b>Background</b>  Despites advances in radiation technology, skull base osteoradionecrosis (ORN) continues to be a rare, devastating, and hard to treat complication of radiotherapy. We present three cases of anterior skull base ORN in a cohort treated with intensity-modulated radiation therapy (IMRT). <b>Case Series</b>  Three patients developed anterior skull base ORN after receiving at least one round of IMRT. ORN was diagnosed through either nasal endoscopy or imaging findings. The first was a 59-year-old woman with a sinonasal squamous cell carcinoma. Her chemoradiation history was notable for reirradiation and a high dose of radiation (143.3 Gy). The second was a 55-year-old man with recurrent nasopharyngeal carcinoma, whose history was notable for a high dose of radiation (∼140 Gy) and for being reirradiated. The final patient was a 37-year-old woman with an unremarkable history who received radiotherapy (65.0 Gy) for an esthesioneuroblastoma. One patient was asymptomatic and did not receive ORN-specific therapy. The other two were treated with a combination of medical and surgical intervention with successful short-term outcomes (no evidence of infection). <b>Conclusion</b>  Anterior skull base ORN can be treated through conservative and surgical means to achieve successful short-term outcomes. Further investigation of long-term outcomes is warranted.</p>","PeriodicalId":44256,"journal":{"name":"Journal of Neurological Surgery Reports","volume":"84 3","pages":"e109-e112"},"PeriodicalIF":0.5,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cc/ba/10-1055-a-2164-8637.PMC10533358.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41137371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Primary Intraosseous Meningioma: A Rare Case of Malignancy with High Proliferative Ability. 原发性骨内脑膜瘤:罕见的高增殖能力恶性肿瘤
IF 0.5 Q4 CLINICAL NEUROLOGY Pub Date : 2023-09-27 eCollection Date: 2023-07-01 DOI: 10.1055/a-2161-7710
Yoshiki Sato, Koichi Mitsuya, Yuko Kakuda, Takuma Oishi, Shoichi Deguchi, Takashi Sugino, Yasuto Akiyama, Takeshi Nagashima, Kenichi Urakami, Yuji Shimoda, Keiichi Ohshima, Nakamasa Hayashi, Ken Yamaguchi

Primary intraosseous meningioma (PIM) is a rare tumor that arises in the skull. Histopathologically, it is generally described as a slow-growing, benign lesion. However, on rare occasions, PIM presents as a malignancy with high proliferative ability, which requires maximal resection, adjuvant radiotherapy, and subsequent careful follow-up. Because of the rarity of such cases, they present a diagnostic challenge with unusual pathological findings. Herein, we report a case of a primary intraosseous anaplastic meningioma with extensive invasion inside and outside the skull, along with the results of whole-genome analysis. Histopathological diagnosis was a World Health Organization grade 3 anaplastic meningioma. In the literature, only two cases of anaplastic PIM have been reported, so its characteristics and treatment are poorly understood. Our patient was successfully treated with tumor resection, followed by intensity-modulated radiation therapy. Follow-up imaging studies revealed no recurrence or distant metastasis, including to lung, liver, and bone, at 8 months after the surgery.

摘要原发性骨内脑膜瘤是一种罕见的颅骨肿瘤。在组织病理学上,它通常被描述为生长缓慢的良性病变。然而,在极少数情况下,PIM表现为具有高增殖能力的恶性肿瘤,需要最大限度的切除、辅助放疗和随后的仔细随访。由于此类病例的罕见性,它们以不同寻常的病理学发现对诊断提出了挑战。在此,我们报告一例原发性骨内间变性脑膜瘤,广泛侵犯颅骨内外,并进行全基因组分析。组织病理学诊断为世界卫生组织3级间变性脑膜瘤。在文献中,仅报道了两例间变性PIM,因此对其特征和治疗方法知之甚少。我们的患者成功地接受了肿瘤切除治疗,随后进行了强度调节放射治疗。随访影像学研究显示,术后8个月无复发或远处转移,包括肺、肝和骨转移。
{"title":"A Primary Intraosseous Meningioma: A Rare Case of Malignancy with High Proliferative Ability.","authors":"Yoshiki Sato,&nbsp;Koichi Mitsuya,&nbsp;Yuko Kakuda,&nbsp;Takuma Oishi,&nbsp;Shoichi Deguchi,&nbsp;Takashi Sugino,&nbsp;Yasuto Akiyama,&nbsp;Takeshi Nagashima,&nbsp;Kenichi Urakami,&nbsp;Yuji Shimoda,&nbsp;Keiichi Ohshima,&nbsp;Nakamasa Hayashi,&nbsp;Ken Yamaguchi","doi":"10.1055/a-2161-7710","DOIUrl":"10.1055/a-2161-7710","url":null,"abstract":"<p><p>Primary intraosseous meningioma (PIM) is a rare tumor that arises in the skull. Histopathologically, it is generally described as a slow-growing, benign lesion. However, on rare occasions, PIM presents as a malignancy with high proliferative ability, which requires maximal resection, adjuvant radiotherapy, and subsequent careful follow-up. Because of the rarity of such cases, they present a diagnostic challenge with unusual pathological findings. Herein, we report a case of a primary intraosseous anaplastic meningioma with extensive invasion inside and outside the skull, along with the results of whole-genome analysis. Histopathological diagnosis was a World Health Organization grade 3 anaplastic meningioma. In the literature, only two cases of anaplastic PIM have been reported, so its characteristics and treatment are poorly understood. Our patient was successfully treated with tumor resection, followed by intensity-modulated radiation therapy. Follow-up imaging studies revealed no recurrence or distant metastasis, including to lung, liver, and bone, at 8 months after the surgery.</p>","PeriodicalId":44256,"journal":{"name":"Journal of Neurological Surgery Reports","volume":"84 1","pages":"e103-e108"},"PeriodicalIF":0.5,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43550925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nasopharyngeal Carcinoma: Case Presentation and Literature Review of Treatment Innovation with Immunotherapy. 鼻咽癌:免疫疗法治疗创新的病例介绍和文献综述。
IF 0.5 Q4 CLINICAL NEUROLOGY Pub Date : 2023-09-27 eCollection Date: 2023-07-01 DOI: 10.1055/s-0043-1774333
Somtochi Okafor, Jameel Muzaffar, David Jang, Ivan El Sayed, Ralph Abi Hachem

Nasopharyngeal carcinoma (NPC), a rare head and neck malignancy, arises from the epithelial lining of nasopharyngeal mucosa. The confluence of various risk factors, such as latent Epstein-Barr virus infection, genetic susceptibility, smoking, alcohol consumption, and high nitrosamine diet, is thought to contribute to NPC pathogenesis. Radiation therapy serves as the mainstay of treatment for early stage while concurrent chemotherapy and radiation are the basis of treatment for locoregional advanced disease with overall 80% five-year survival rate. Recurrent or metastatic disease pose treatment challenges as reirradiation, repeat cycles of chemotherapy, and surgery follow with high likelihood of treatment toxicity or postoperative morbidities. Typically reserved for nonresectable recurrent or metastatic disease, immunotherapy serves as novel treatment for NPC. NPC tumor microenvironment predominated by a dense infiltrate of immune cells hosts an ideal target for immunotherapy. Several clinical trials have investigated the efficacy of anti-programmed cell death protein 1 antibodies such as pembrolizumab, nivolumab, and camrelizumab with promising results. Treatment of recurrent and metastatic NPC remains a challenge; however, the advent of immunotherapy has provided additional options and potential for preventative and therapeutic measures.

鼻咽癌是一种罕见的头颈部恶性肿瘤,起源于鼻咽粘膜上皮。各种危险因素的共同作用,如潜在的EB病毒感染、遗传易感性、吸烟、饮酒和高亚硝胺饮食,被认为是导致NPC发病的原因。放疗是早期治疗的主要手段,同时化疗和放疗是局部晚期疾病治疗的基础,总的五年生存率为80%。复发或转移性疾病给治疗带来了挑战,因为再次放疗、重复化疗周期和手术后很可能出现治疗毒性或术后并发症。免疫疗法通常是为无复发或转移性疾病保留的,是NPC的新治疗方法。以免疫细胞密集浸润为主的NPC肿瘤微环境是免疫治疗的理想靶点。一些临床试验已经调查了抗程序性细胞死亡蛋白1抗体的疗效,如pembrolizumab、nivolumab和camrelizumab,结果很有希望。复发性和转移性鼻咽癌的治疗仍然是一个挑战;然而,免疫疗法的出现为预防和治疗措施提供了额外的选择和潜力。
{"title":"Nasopharyngeal Carcinoma: Case Presentation and Literature Review of Treatment Innovation with Immunotherapy.","authors":"Somtochi Okafor, Jameel Muzaffar, David Jang, Ivan El Sayed, Ralph Abi Hachem","doi":"10.1055/s-0043-1774333","DOIUrl":"10.1055/s-0043-1774333","url":null,"abstract":"<p><p>Nasopharyngeal carcinoma (NPC), a rare head and neck malignancy, arises from the epithelial lining of nasopharyngeal mucosa. The confluence of various risk factors, such as latent Epstein-Barr virus infection, genetic susceptibility, smoking, alcohol consumption, and high nitrosamine diet, is thought to contribute to NPC pathogenesis. Radiation therapy serves as the mainstay of treatment for early stage while concurrent chemotherapy and radiation are the basis of treatment for locoregional advanced disease with overall 80% five-year survival rate. Recurrent or metastatic disease pose treatment challenges as reirradiation, repeat cycles of chemotherapy, and surgery follow with high likelihood of treatment toxicity or postoperative morbidities. Typically reserved for nonresectable recurrent or metastatic disease, immunotherapy serves as novel treatment for NPC. NPC tumor microenvironment predominated by a dense infiltrate of immune cells hosts an ideal target for immunotherapy. Several clinical trials have investigated the efficacy of anti-programmed cell death protein 1 antibodies such as pembrolizumab, nivolumab, and camrelizumab with promising results. Treatment of recurrent and metastatic NPC remains a challenge; however, the advent of immunotherapy has provided additional options and potential for preventative and therapeutic measures.</p>","PeriodicalId":44256,"journal":{"name":"Journal of Neurological Surgery Reports","volume":"84 3","pages":"e113-e115"},"PeriodicalIF":0.5,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547533/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41169006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TransOrbital NeuroEndoscopic Surgery for Biopsy of the Left Cavernous Sinus: A Literature Review, Case Report, and Cadaveric Proof of Concept. 左海绵窦活检的经眶神经内窥镜手术:文献综述、病例报告和尸体概念证明。
IF 0.5 Q4 CLINICAL NEUROLOGY Pub Date : 2023-09-27 eCollection Date: 2023-07-01 DOI: 10.1055/a-2155-2419
Natasha L Frontera, Julio Rosado-Philippi, Francisco Del Valle Díaz, Alejandra Santiago Díaz, Adriana Vázquez Medina, Arnaldo Figueroa, Natalia González, Gustavo Pradilla, Tomas Garzón, Julio Rodríguez, Luisam Tarrats, Miguel Mayol Del Valle

The aim of this report is to describe TransOrbital NeuroEndoscopic Surgery (TONES) as a safe alternative for obtaining a cavernous sinus (CS) biopsy. We describe this technique in a patient with a diffuse large B cell lymphoma mimicking Tolosa-Hunt's syndrome. Articles were gathered querying PubMed, Embase, and Scopus databases with terms related to a "transorbital neuroendoscopic approach." The literature search was performed by two independent authors (N.L.F. and J.R.), with inconsistencies resolved by the senior author (M.M.D.V.). After screening abstracts for relevance, full-length articles were reviewed for pertinent variables. A comparison was conducted with the illustrative case of a 69-year-old woman who presented to the emergency department with vertigo, ophthalmoplegia, and diplopia for 2 months. A brain magnetic resonance imaging revealed an infiltrative lesion at the left CS. A presumptive diagnosis of Tolosa-Hunt syndrome was made, but a confirmatory biopsy was performed using TONES. Based on our cadaveric study, literature review, and case report, the TONES approach was safe, effective for tissue diagnosis, and associated with minor morbidity and reduced hospital stay. Additional prospective studies are required to study its viability and safety in a larger group of patients.

本报告的目的是描述经眶神经内窥镜手术(TONES)作为获得海绵窦(CS)活检的安全替代方案。我们在一名患有弥漫性大B细胞淋巴瘤的患者身上描述了这项技术,该淋巴瘤模仿Tolosa-Hunt's综合征。收集的文章查询PubMed、Embase和Scopus数据库,其中包含与“经眶神经内窥镜方法”相关的术语。文献检索由两位独立作者(N.L.F.和J.R.)进行,不一致之处由资深作者(M.M.D.V.)解决。在筛选摘要的相关性后,对全文文章进行相关变量的审查。将其与一例69岁的妇女进行比较,该妇女因眩晕、眼肌麻痹和复视在急诊科就诊2个月。脑部磁共振成像显示左侧CS有浸润性病变。对Tolosa-Hunt-综合征进行了推定诊断,但使用TONES进行了确认性活检。根据我们的尸体研究、文献综述和病例报告,TONES方法是安全、有效的组织诊断方法,并且发病率低,住院时间短。需要进行更多的前瞻性研究,以在更大的患者群体中研究其可行性和安全性。
{"title":"TransOrbital NeuroEndoscopic Surgery for Biopsy of the Left Cavernous Sinus: A Literature Review, Case Report, and Cadaveric Proof of Concept.","authors":"Natasha L Frontera,&nbsp;Julio Rosado-Philippi,&nbsp;Francisco Del Valle Díaz,&nbsp;Alejandra Santiago Díaz,&nbsp;Adriana Vázquez Medina,&nbsp;Arnaldo Figueroa,&nbsp;Natalia González,&nbsp;Gustavo Pradilla,&nbsp;Tomas Garzón,&nbsp;Julio Rodríguez,&nbsp;Luisam Tarrats,&nbsp;Miguel Mayol Del Valle","doi":"10.1055/a-2155-2419","DOIUrl":"https://doi.org/10.1055/a-2155-2419","url":null,"abstract":"<p><p>The aim of this report is to describe TransOrbital NeuroEndoscopic Surgery (TONES) as a safe alternative for obtaining a cavernous sinus (CS) biopsy. We describe this technique in a patient with a diffuse large B cell lymphoma mimicking Tolosa-Hunt's syndrome. Articles were gathered querying PubMed, Embase, and Scopus databases with terms related to a \"transorbital neuroendoscopic approach.\" The literature search was performed by two independent authors (N.L.F. and J.R.), with inconsistencies resolved by the senior author (M.M.D.V.). After screening abstracts for relevance, full-length articles were reviewed for pertinent variables. A comparison was conducted with the illustrative case of a 69-year-old woman who presented to the emergency department with vertigo, ophthalmoplegia, and diplopia for 2 months. A brain magnetic resonance imaging revealed an infiltrative lesion at the left CS. A presumptive diagnosis of Tolosa-Hunt syndrome was made, but a confirmatory biopsy was performed using TONES. Based on our cadaveric study, literature review, and case report, the TONES approach was safe, effective for tissue diagnosis, and associated with minor morbidity and reduced hospital stay. Additional prospective studies are required to study its viability and safety in a larger group of patients.</p>","PeriodicalId":44256,"journal":{"name":"Journal of Neurological Surgery Reports","volume":"84 3","pages":"e116-e123"},"PeriodicalIF":0.5,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/57/23/10-1055-a-2155-2419.PMC10533359.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41172367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systematic review of WHO grade 4 astrocytoma in the cerebellopontine angle: the impact of anatomic corridor on treatment options and outcomes 世卫组织4级脑桥小脑角星形细胞瘤的系统回顾:解剖通道对治疗方案和结果的影响
IF 0.5 Q4 CLINICAL NEUROLOGY Pub Date : 2023-09-08 DOI: 10.1055/a-2172-7770
D. Dang, Andrew Gong, John V. Dang, Luke A. Mugge, Seth Mansinghani, Mateo Ziu, Adam L. Cohen, Nilesh Vyas
Background: Despite advances in multimodal oncologic therapies and molecular genetics, overall survival (OS) for high-grade astrocytomas remains poor. We present an illustrative case and systematic review of rare, predominantly extra-axial WHO grade 4 astrocytomas located within the cerebellopontine angle (CPA) and explore the impact of anatomic location on diagnosis, management, and outcomes.Methods: A systematic review of adult patients with predominantly extra-axial WHO grade 4 CPA astrocytomas was conducted following the PRISMA guidelines through December 2022. Results: 18 articles were included comprising 21 astrocytomas: 13 exophytic tumors arising from cerebellopontine parenchyma, and 8 tumors originating from a cranial nerve root entry zone. Median OS was 15 months with one-third of cases demonstrating delayed diagnosis. Gross total resection, molecular genetic profiling, and use of ancillary treatment were low. We report the only patient with an integrated IDH-1 mutant diagnosis, who, after subtotal resection and chemoradiation, remains alive at 40 months without progression.Conclusion: The deep conical-shaped corridor and abundance of eloquent tissue of the CPA significantly limits both surgical resection and utility of device-based therapies in this region. Prompt diagnosis, molecular characterization, and systemic therapeutic advances serve as the predominant means to optimize survival for patients with rare skull base astrocytomas.
背景:尽管多模式肿瘤学治疗和分子遗传学取得了进展,但高级别星形细胞瘤的总生存率(OS)仍然很低。我们对位于桥小脑角(CPA)内的罕见、主要为轴外世界卫生组织4级星形细胞瘤进行了说明性病例和系统回顾,并探讨了解剖位置对诊断、管理和结果的影响。方法:根据PRISMA指南至2022年12月,对以轴外世界卫生组织4级CPA星形细胞瘤为主的成年患者进行系统回顾。结果:18篇文章包括21例星形细胞瘤:13例源于桥小脑实质的外生肿瘤,8例源于颅神经根进入区。中位OS为15个月,三分之一的病例显示诊断延迟。大体全切除、分子遗传图谱和辅助治疗的使用率较低。我们报告了唯一一位被综合诊断为IDH-1突变的患者,他在大部切除和放化疗后,在40个月时仍然存活,没有进展。结论:CPA的深圆锥形通道和丰富的有说服力的组织显著限制了该区域的手术切除和器械治疗的实用性。及时诊断、分子表征和系统治疗进展是优化罕见颅底星形细胞瘤患者生存的主要手段。
{"title":"Systematic review of WHO grade 4 astrocytoma in the cerebellopontine angle: the impact of anatomic corridor on treatment options and outcomes","authors":"D. Dang, Andrew Gong, John V. Dang, Luke A. Mugge, Seth Mansinghani, Mateo Ziu, Adam L. Cohen, Nilesh Vyas","doi":"10.1055/a-2172-7770","DOIUrl":"https://doi.org/10.1055/a-2172-7770","url":null,"abstract":"Background: Despite advances in multimodal oncologic therapies and molecular genetics, overall survival (OS) for high-grade astrocytomas remains poor. We present an illustrative case and systematic review of rare, predominantly extra-axial WHO grade 4 astrocytomas located within the cerebellopontine angle (CPA) and explore the impact of anatomic location on diagnosis, management, and outcomes.\u0000\u0000Methods: A systematic review of adult patients with predominantly extra-axial WHO grade 4 CPA astrocytomas was conducted following the PRISMA guidelines through December 2022. \u0000\u0000Results: 18 articles were included comprising 21 astrocytomas: 13 exophytic tumors arising from cerebellopontine parenchyma, and 8 tumors originating from a cranial nerve root entry zone. Median OS was 15 months with one-third of cases demonstrating delayed diagnosis. Gross total resection, molecular genetic profiling, and use of ancillary treatment were low. We report the only patient with an integrated IDH-1 mutant diagnosis, who, after subtotal resection and chemoradiation, remains alive at 40 months without progression.\u0000\u0000Conclusion: The deep conical-shaped corridor and abundance of eloquent tissue of the CPA significantly limits both surgical resection and utility of device-based therapies in this region. Prompt diagnosis, molecular characterization, and systemic therapeutic advances serve as the predominant means to optimize survival for patients with rare skull base astrocytomas.","PeriodicalId":44256,"journal":{"name":"Journal of Neurological Surgery Reports","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43432640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surgical Management of Meningiomas Involving the Torcula, Transverse Sinus, and Jugular Bulb: A Technical Note and Review of the Literature. 涉及鸟嘴、横窦和颈静脉球的脑膜瘤的手术治疗:技术说明和文献综述。
IF 0.6 Q4 CLINICAL NEUROLOGY Pub Date : 2023-08-25 eCollection Date: 2023-07-01 DOI: 10.1055/s-0043-1772201
Robert G Power, Fred C Lam, Anthony C Whitton, Sunjay Sharma, Ekkehard M Kasper

Meningiomas that invade the confluens sinuum are rare and require extensive preoperative planning. Here, we describe the surgical and radio-oncological management of an aggressive large occipital meningioma invading the superior sagittal sinus, torcula, right and left transverse sinus down to the level of the jugular bulb in a 21-year-old female patient. Details of the surgical approach are presented to highlight the planned staged resection of this tumor at the level of the torcula to initially debulk the lesion while preserving venous outflow through the patent's sinus. Once the tumor fully occluded the confluens, a second-stage en bloc resection ensued. Postsurgical adjuvant radiation therapy was delivered via fractionated external beam therapy which has provided local control of the tumor since. This case is being discussed in the context of the pertinent literature to demonstrate the highly complex interdisciplinary and staged management of partially intravascular meningiomas involving the major venous sinuses.

侵犯蝶窦的脑膜瘤非常罕见,需要进行广泛的术前规划。在此,我们介绍了一名 21 岁女性患者的手术和放射肿瘤学治疗情况,该患者的枕骨大脑膜瘤侵犯了上矢状窦、蝶窦、左右横窦直至颈静脉球。本文介绍了手术方法的细节,重点说明了计划在蝶窦水平对该肿瘤进行的分期切除术,以首先清除病灶,同时保留通过专利窦的静脉流出。一旦肿瘤完全堵塞了汇合处,就进行第二阶段的整体切除。手术后通过分次体外射束疗法进行了辅助放疗,自此肿瘤得到了局部控制。本文结合相关文献对该病例进行了讨论,以展示涉及大静脉窦的部分血管内脑膜瘤的跨学科分期治疗的高度复杂性。
{"title":"Surgical Management of Meningiomas Involving the Torcula, Transverse Sinus, and Jugular Bulb: A Technical Note and Review of the Literature.","authors":"Robert G Power, Fred C Lam, Anthony C Whitton, Sunjay Sharma, Ekkehard M Kasper","doi":"10.1055/s-0043-1772201","DOIUrl":"10.1055/s-0043-1772201","url":null,"abstract":"<p><p>Meningiomas that invade the confluens sinuum are rare and require extensive preoperative planning. Here, we describe the surgical and radio-oncological management of an aggressive large occipital meningioma invading the superior sagittal sinus, torcula, right and left transverse sinus down to the level of the jugular bulb in a 21-year-old female patient. Details of the surgical approach are presented to highlight the planned staged resection of this tumor at the level of the torcula to initially debulk the lesion while preserving venous outflow through the patent's sinus. Once the tumor fully occluded the confluens, a second-stage en bloc resection ensued. Postsurgical adjuvant radiation therapy was delivered via fractionated external beam therapy which has provided local control of the tumor since. This case is being discussed in the context of the pertinent literature to demonstrate the highly complex interdisciplinary and staged management of partially intravascular meningiomas involving the major venous sinuses.</p>","PeriodicalId":44256,"journal":{"name":"Journal of Neurological Surgery Reports","volume":"84 3","pages":"e92-e102"},"PeriodicalIF":0.6,"publicationDate":"2023-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5b/e2/10-1055-s-0043-1772201.PMC10457152.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10107814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nasopharyngeal Carcinoma: Case Presentation and Literature Review of Treatment Innovation with Immunotherapy 鼻咽癌:免疫治疗创新的病例报告及文献回顾
Q4 CLINICAL NEUROLOGY Pub Date : 2023-07-01 DOI: 10.1055/a-2148-2429
Somtochi I Okafor, Jameel Muzaffar, David Jang, Ivan H El-Sayed, Ralph Abi Hachem
Abstract Nasopharyngeal carcinoma (NPC), a rare head and neck malignancy, arises from the epithelial lining of nasopharyngeal mucosa. The confluence of various risk factors, such as latent Epstein–Barr virus infection, genetic susceptibility, smoking, alcohol consumption, and high nitrosamine diet, is thought to contribute to NPC pathogenesis. Radiation therapy serves as the mainstay of treatment for early stage while concurrent chemotherapy and radiation are the basis of treatment for locoregional advanced disease with overall 80% five-year survival rate. Recurrent or metastatic disease pose treatment challenges as reirradiation, repeat cycles of chemotherapy, and surgery follow with high likelihood of treatment toxicity or postoperative morbidities. Typically reserved for nonresectable recurrent or metastatic disease, immunotherapy serves as novel treatment for NPC. NPC tumor microenvironment predominated by a dense infiltrate of immune cells hosts an ideal target for immunotherapy. Several clinical trials have investigated the efficacy of anti-programmed cell death protein 1 antibodies such as pembrolizumab, nivolumab, and camrelizumab with promising results. Treatment of recurrent and metastatic NPC remains a challenge; however, the advent of immunotherapy has provided additional options and potential for preventative and therapeutic measures.
摘要鼻咽癌是一种罕见的头颈部恶性肿瘤,起源于鼻咽部粘膜上皮。多种危险因素,如潜伏性eb病毒感染、遗传易感性、吸烟、饮酒、高亚硝胺饮食等,被认为是鼻咽癌发病的共同因素。放射治疗是早期治疗的主要方法,而同时进行化疗和放疗是局部晚期疾病治疗的基础,总体5年生存率为80%。复发性或转移性疾病给治疗带来挑战,因为再照射、重复化疗周期和手术之后很可能出现治疗毒性或术后发病率。免疫治疗通常用于不可切除的复发或转移性疾病,是鼻咽癌的一种新治疗方法。以免疫细胞密集浸润为主的鼻咽癌微环境是免疫治疗的理想靶点。一些临床试验已经研究了抗程序性细胞死亡蛋白1抗体(如pembrolizumab、nivolumab和camrelizumab)的疗效,并取得了令人鼓舞的结果。治疗复发和转移性鼻咽癌仍然是一个挑战;然而,免疫疗法的出现为预防和治疗措施提供了额外的选择和潜力。
{"title":"Nasopharyngeal Carcinoma: Case Presentation and Literature Review of Treatment Innovation with Immunotherapy","authors":"Somtochi I Okafor, Jameel Muzaffar, David Jang, Ivan H El-Sayed, Ralph Abi Hachem","doi":"10.1055/a-2148-2429","DOIUrl":"https://doi.org/10.1055/a-2148-2429","url":null,"abstract":"Abstract Nasopharyngeal carcinoma (NPC), a rare head and neck malignancy, arises from the epithelial lining of nasopharyngeal mucosa. The confluence of various risk factors, such as latent Epstein–Barr virus infection, genetic susceptibility, smoking, alcohol consumption, and high nitrosamine diet, is thought to contribute to NPC pathogenesis. Radiation therapy serves as the mainstay of treatment for early stage while concurrent chemotherapy and radiation are the basis of treatment for locoregional advanced disease with overall 80% five-year survival rate. Recurrent or metastatic disease pose treatment challenges as reirradiation, repeat cycles of chemotherapy, and surgery follow with high likelihood of treatment toxicity or postoperative morbidities. Typically reserved for nonresectable recurrent or metastatic disease, immunotherapy serves as novel treatment for NPC. NPC tumor microenvironment predominated by a dense infiltrate of immune cells hosts an ideal target for immunotherapy. Several clinical trials have investigated the efficacy of anti-programmed cell death protein 1 antibodies such as pembrolizumab, nivolumab, and camrelizumab with promising results. Treatment of recurrent and metastatic NPC remains a challenge; however, the advent of immunotherapy has provided additional options and potential for preventative and therapeutic measures.","PeriodicalId":44256,"journal":{"name":"Journal of Neurological Surgery Reports","volume":"55 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135712048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Infarctive Apoplexy of Previously Healthy Pituitary Glands: A Small Case Series and Literature Review. 先前健康垂体的梗死性中风:一个小病例系列和文献回顾。
IF 0.5 Q4 CLINICAL NEUROLOGY Pub Date : 2023-07-01 DOI: 10.1055/s-0043-1770788
Abigail Funari, Seth S Jeong, Isabella L Pecorari, Isabella Flaquer, Cassidy L Anderson, Vijay Agarwal

Introduction  We present two cases of suspected pituitary apoplexy found instead to be infarcted pituitary glands without histopathologic evidence of neoplastic cells, likely resulting from spontaneous infarction of previously healthy pituitary glands. Case Presentations  The first case is a 55-year-old man who presented with a pulsating headache, nausea, and several months of decreased libido, polyuria, and polydipsia. Magnetic resonance imaging (MRI) revealed a rim-enhancing sellar/suprasellar mass with evidence of recent hemorrhage on the right. Testosterone, follicle-stimulating hormone, and luteinizing hormone levels were suppressed. Analysis of the resected specimen showed fibrocollagenous tissue with evidence of old hemorrhage and microscopic focus of necrotic tissue. The second case is a 56-year-old man who presented with a throbbing headache, associated nausea, and 6 weeks of polyuria and polydipsia. Testosterone levels were found to be low, and 8-hour water deprivation test showed evidence for partial diabetes insipidus. MRI revealed a mass on the right side of the pituitary gland, with evidence of likely hemorrhage on the left. Analysis of the resected specimen showed necrotic tissue without neoplastic cells. Conclusion  When evaluating small pituitary lesions in patients presenting with indolent onset of pituitary insufficiency, there should be a high degree of suspicion for an infarcted pituitary gland.

我们报告了两例疑似垂体中风的病例,结果发现是垂体梗死,没有肿瘤细胞的组织病理学证据,可能是由先前健康的垂体自发梗死引起的。第一例患者为55岁男性,表现为搏动性头痛、恶心、性欲下降、多尿和烦渴数月。磁共振成像(MRI)显示右侧鞍/鞍上肿块边缘增强,有近期出血迹象。睾酮、促卵泡激素和黄体生成素水平均受到抑制。切除标本的分析显示纤维胶原组织,有老出血的证据和显微镜下坏死组织的焦点。第二例为56岁男性,表现为抽动性头痛,伴恶心,6周多尿和烦渴。睾酮水平较低,8小时缺水试验显示部分尿崩症。MRI显示脑下垂体右侧有肿块,左侧可能有出血迹象。切除标本的分析显示坏死组织无肿瘤细胞。结论在评估以垂体功能不全为首发症状的患者的垂体小病变时,应高度怀疑垂体梗死。
{"title":"Infarctive Apoplexy of Previously Healthy Pituitary Glands: A Small Case Series and Literature Review.","authors":"Abigail Funari,&nbsp;Seth S Jeong,&nbsp;Isabella L Pecorari,&nbsp;Isabella Flaquer,&nbsp;Cassidy L Anderson,&nbsp;Vijay Agarwal","doi":"10.1055/s-0043-1770788","DOIUrl":"https://doi.org/10.1055/s-0043-1770788","url":null,"abstract":"<p><p><b>Introduction</b>  We present two cases of suspected pituitary apoplexy found instead to be infarcted pituitary glands without histopathologic evidence of neoplastic cells, likely resulting from spontaneous infarction of previously healthy pituitary glands. <b>Case Presentations</b>  The first case is a 55-year-old man who presented with a pulsating headache, nausea, and several months of decreased libido, polyuria, and polydipsia. Magnetic resonance imaging (MRI) revealed a rim-enhancing sellar/suprasellar mass with evidence of recent hemorrhage on the right. Testosterone, follicle-stimulating hormone, and luteinizing hormone levels were suppressed. Analysis of the resected specimen showed fibrocollagenous tissue with evidence of old hemorrhage and microscopic focus of necrotic tissue. The second case is a 56-year-old man who presented with a throbbing headache, associated nausea, and 6 weeks of polyuria and polydipsia. Testosterone levels were found to be low, and 8-hour water deprivation test showed evidence for partial diabetes insipidus. MRI revealed a mass on the right side of the pituitary gland, with evidence of likely hemorrhage on the left. Analysis of the resected specimen showed necrotic tissue without neoplastic cells. <b>Conclusion</b>  When evaluating small pituitary lesions in patients presenting with indolent onset of pituitary insufficiency, there should be a high degree of suspicion for an infarcted pituitary gland.</p>","PeriodicalId":44256,"journal":{"name":"Journal of Neurological Surgery Reports","volume":"84 3","pages":"e71-e79"},"PeriodicalIF":0.5,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2e/67/10-1055-s-0043-1770788.PMC10365896.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9875701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Journal of Neurological Surgery Reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1